3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance
Patent inventors: Krzysztof Zabłocki, Janusz Wasilweski

A subject of the invention is a compound 3-dodecylsulfanyl-butyric acid for use as a drug, especially for use in the treatment and prevention of the development of insulin resistance. The invention also relates to a pharmaceutical composition containing 3-dodecylsulfanyl-butyric acid as an active ingredient, and to the use of 3-dodecylsulfanyl-butyric acid for the manufacture of a drug for the prevention of insulin resistance.

Patent was granted in Poland. Nencki Institute is the co-owner of the applicable rights with University of Warmia and Mazury. Institute is the leader of patent protection and commercialization related activities.

For more information contact Technology Transfer Office.

Application number:
P.414785 (13 Nov 2015)
Patent number:
PL 228077 (28 Feb 2018)
Patent status: